Pharmaceuticals - Community Register

  

Community list of not active veterinary medicinal products


WITHDRAWN  

Product information

Invented name: Zubrin
Auth. number : EU/2/00/028
INN : tepoxalin
ATC: Anatomical main group: QM - Musculo-skeletal system
Therapeutic subgroup: QM01 - Antiinflammatory and antirheumatic products
Pharmacological subgroup: QM01A - Antiinflammatory and antirheumatic products, non-steroids
Chemical subgroup: QM01AE - Propionic acid derivatives
Chemical substance: QM01AE92 - Tepoxalin
(See WHO ATCvet Index)
Indication: Reduction of inflammation and relief of pain caused by acute musculoskeleatl disorders or acute exacerbation of chronic musoloskeletal disorders
Marketing Authorisation Holder: Intervet International B.V.
Wim de Körverstraat 35, NL-5831 AN Boxmeer, Nederland
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
14/03/2001 Centralised - Authorisation EMEA/V/C/57 (2001)522 of 13/03/2001
09/07/2001 Centralised - Variation (no change in Commission Decision) EMEA/V/C/57/I/10
20/07/2001 Centralised - Variation EMEA/V/C/57/I/2, 8, EMEA/V/C/57/N/9 (2001)2025 of 19/07/2001
20/12/2001 Centralised - Variation EMEA/V/C/57/II/1 (2001)4204 of 17/12/2001
18/06/2002 Centralised - Variation (no change in Commission Decision) EMEA/V/C/57/I/13
12/11/2002 Centralised - Variation (no change in Commission Decision) EMEA/V/C/57/I/15
12/11/2002 Centralised - Variation (no change in Commission Decision) EMEA/V/C/57/I/14
23/10/2003 Centralised - Variation (no change in Commission Decision) EMEA/V/C/57/I/17
03/02/2004 Centralised - Variation EMEA/V/C/57/II/16 (2004)292 of 29/01/2004
23/04/2004 Centralised - Notification EMEA/V/C/57/N/18
Updated with Decision(2005)6015 of 23/12/2005
25/04/2005 Centralised - Variation EMEA/V/C/57/IA/20
Updated with Decision(2005)6015 of 23/12/2005
23/09/2005 Centralised - Variation EMEA/V/C/57/IB/21
Updated with Decision(2005)6015 of 23/12/2005
28/12/2005 Centralised - Variation (2005)6015 of 23/12/2005
23/01/2006 Centralised - Variation EMEA/V/C/57/II/19 (2006)126 of 19/01/2006
15/03/2006 Corrigendum (2005)6015 corr of 13/03/2006
17/03/2006 Centralised - Renewal EMEA/V/C/57/R/22 (2006)875 of 15/03/2006
21/12/2006 Centralised - Variation (no change in Commission Decision) EMEA/V/C/57/IA/24
21/12/2006 Centralised - Variation (no change in Commission Decision) EMEA/V/C/57/IA/23
09/03/2007 Centralised - Variation (no change in Commission Decision) EMEA/V/C/57/IA/25
07/12/2007 Centralised - Variation (no change in Commission Decision) EMEA/V/C/57/IA/28
29/01/2008 Centralised - Variation EMEA/V/C/57/IA/30
Updated with Decision(2008)4679 of 25/08/2008
27/08/2008 Centralised - Variation (2008)4679 of 25/08/2008
23/03/2011 Centralised - Transfer Marketing Authorisation Holder EMEA/V/C/57/T/31 (2011)1935 of 18/03/2011
01/06/2011 Centralised - Variation EMEA/V/C/57/IB/32
Updated with Decision(2012)637 of 31/01/2012
02/02/2012 Centralised - Variation (2012)637 of 31/01/2012
22/03/2012 Centralised - Withdrawal (2012)1938 of 19/03/2012